NetworkNewsBreaks – Celsion Corp. (NASDAQ: CLSN) Presents “Encouraging” OVATION Study Results; Shares Surge on Heavy Volume
Shares of Celsion (NASDAQ: CLSN) are up 57.8% on volume of 15.98 million in mid-day trade after the oncology drug development company issued an update on its OVATION study, a phase Ib dose escalating clinical trial assessing the combination of GEN-1, Celsion’s DNA-based immunotherapy, with the standard of care for the treatment of newly diagnosed patients with advanced ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery. “The OVATION study has accrued patients from four major research cancer centers. We have seen highly promising clinical findings including a patient with a complete pathological response along with a very high…







